Beam Therapeutics Inc.
BEAM
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.1B
$29.66
▲ +0.68%
P/E
-34.49
Mkt Cap
$3.1B
52-Wk Range
$19.36–$38.26
52-Week Range
$19.36 - $38.26
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 48.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Base Editing Technology
- Broad Therapeutic Pipeline
- Strategic Research Collaborations
- Advanced Gene Modification Approach
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
Revenue decline expected
Advancing Genetic Disease Treatments
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Stable
-0.4% over 3m
Quality
Thin
Emerging growth company (158% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying BEAM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of -$1.18 vs -$1.11 consensus (-6.3% surprise). Revenue of $490.0K vs $16.4M expected (-97.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-6.3%
Revenue trend · last 8Q
—
-90%
+1%
-28%
-32%
+280%
+325%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$14.3M
$30.1M
$7.5M
$8.5M
$9.7M
$114.1M
$31.7M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 10, 2026
vs Industry
How BEAM stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related